Across TCGA pan-cancer cohorts, TOX mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TOX data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TOX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TOX expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where TOX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.373	0.822	.013	33	view →
LUAD	DFS	Tertile	II,III,IV	0.786	0.325	.027	2	view →
LSCC	DFS	Median	III,IV	0.970	0.651	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TOX tumor-vs-normal RNA expression · all TOX data types